We provide personalized solutions for a healthy life by
analyzing your genomic features.
Based on genetic factors identified through your personal genome sequence, we predict the risk of cancer and provide personalized treatment information by
analyzing mutations in oncogenes.
SERVICE
Cancer risk prediction
Cancers occur due to various causes, but some cancers are caused by genetic mutations of specific inherited genes.
People who have such cancer-related mutations are exposed to far more risk of cancer than others. Hereditary cancers are caused by gene abnormalities inherited from parents, and the incidence of cancer in the same family is high. Thus, early detection and identification of the exact cause through gene diagnosis is required. The most commonly known hereditary cancers are breast cancer, ovarian cancer, and colon cancer. In regard to incidence of breast cancer, 5% - 10% is known to be genetically caused, and about more than half are caused by abnormalities in genes called BRCA1 and BRCA2. In addition, having genes that cause various cancers will dramatically increase the incidence of cancer.
Hereditary Cancer Panel
The heredity cancer panel diagnoses the hereditary risk of cancer by analyzing the causative gene related to hereditary cancer. Mutations of a total of 16 genes including BRCA1/2 genes, and genes related to Lynch syndrome, which is the main cause of colon cancer, are analyzed.
| Gene List | Target | Description (related cancer type) |
|---|---|---|
| APC, MUTYH | Large Intestine | Germline mutations associated with familial adenomatous polyposis (FAP) |
| BRCA1, BRCA2 | Breast Ovary | Related to breast/ovarian cancer |
| CDH1 | Stomach Large Intestine | Responsible for cell-to-cell adhesion llmplicated in cancer progression and metastasis |
| EPCAM, PMS2, MLH1, MSH2, MSH6 | Large Intestine Rectum | Related to the mismatch repair of DNA Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC) |
| MEN1 | Endocrine System | Multiple endocrine neoplasia type 1 (MEN-1 syndrome) Familial neoplasia affecting the network of hormone-producing glands |
| PTEN | Thyroid Breast | Cowden syndrome Tumor - suppressor gene |
| RB1 | Eye | Retinoblastoma |
| RET | Endocrine System Thyroid | Proto-oncogene Multiple endocrine neoplasia type 2 Medullary thyroid carcinoma |
| TP53 | Breast Bone Etc. | Li - Fraumeni syndrome |
| VHL | Eye Kidny Central Nervous System | Tumor - suppressor gene von Hippel - Lindau Syndrome |
BRCA1/2 Gene Test
All areas of the BRCA1/2 gene, which is the main cause of hereditary breast cancer, are analyzed to diagnose a person’s risk of breast cancer.
Mutations in the BRCA 1/2 gene greatly increase the risk of breast cancer.
Clinical diagnosis-related service items cannot be requested personally, and inquiries through professional medical personnel are required to use the service.
Analysis of causes of cancer
This service tracks the cause of cancer and provides key information for personalized treatment by analyzing mutations in the genes
involved in cancer development using DNA extracted from cancer patients' tumor samples.
Until now, cancers were classified in a histopathological manner, but recently, gene analysis is performed on cancer tissue, and cancers are subdivided into groups.
This contributes to improved response (about 75% of patients exhibit different effects when the same anticancer drug is prescribed) and provides personalized treatment for cancer
patients while minimizing adverse effects.
※ Source: Pao W et al. New driver mutations in non-small-cell lung cancer Lancet Oncol. 2011 Feb; 12(2): 175-80
Clinical diagnosis-related service items cannot be requested personally, and inquiries through professional medical personnel are required to use the service.
Cancer Occurrence Monitoring
When cancer occurs in the body, there are NDA fragments detached from cancer cells in the blood.
This is called ctDNA (circulating tumor DNA). When ctDNA is checked regularly, cancer cells can be detected early and prompt measures can be taken.
Unlike existing biopsies, this test can be performed by simply collecting blood, which makes regular checkups more efficient. However, theistest is not widely given because the levels of
ctDNA are different by type of cancer and individual, making detection very difficult. Macrogen is expanding this service by continuously making technical improvements.
Clinical diagnosis-related service items cannot be requested personally, and inquiries through professional medical personnel are required to use the service.